肝细胞癌患者的乙型肝炎病毒治疗可延长生存期并降低癌症

StephenW

Clin Exp Hepatol. 2018 Sep;4(3):210-216. doi: 10.5114/ceh.2018.78127. Epub 2018 Sep 10.
Hepatitis B virus treatment in hepatocellular carcinoma patients prolongs survival and reduces the risk of cancer recurrence.
Pazgan-Simon M1, Simon KA2, Jarowicz E3, Rotter K1, Szymanek-Pasternak A2, Zuwała-Jagiełło J4.
Author information

1
    Department of Infectious Disease 1, Regional Specialistic Hospital, Wroclaw, Poland.
2
    Department of Infectious Disease and Hepatology, Wroclaw Medical University, Wroclaw, Poland.
3
    Department of Infectious Disease 2, Regional Specialistic Hospital, Wroclaw, Poland.
4
    Department of Pharmacutical Biochemistry, Wroclaw Medical University, Wroclaw, Poland.

Abstract

Chronic hepatitis B virus (HBV) infection and HBV-related liver disease are estimated to affect about 240 million people worldwide. Now that a vaccine is available, the number of new HBV infection cases has plummeted. Yet, there are still regions with very high incidence of HBV. Hepatocellular carcinoma (HCC) is the fourth to six most common malignancy in men and the ninth most common malignancy in women worldwide. 54% of all HCC cases are HBV-associated, making it the most common cause of cancer worldwide. Hepatitis B therapy prevents progression of chronic hepatitis to cirrhosis and HCC development, but even with the best HBV treatment, such patients are still at risk of HCC. Also in patients after transarterial chemoembolization (TACE), liver resection (hepatectomy) or liver transplant, suppression of hepatitis B virus (HBV) improves patient survival. In this paper we present current possibilities of HCC and HBV treatment, which lead to improved survival and quality of life.
KEYWORDS:

HBV treatment; HCC; HCC treatment

PMID:
    30324148
PMCID:
    PMC6185928
DOI:
    10.5114/ceh.2018.78127

StephenW

Clin Exp Hepatol。 2018年9月; 4（3）：210-216。 doi：10.5114 / ceh.2018.78127。 Epub 2018年9月10日。
肝细胞癌患者的乙型肝炎病毒治疗可延长生存期并降低癌症复发的风险。
Pazgan-Simon M1，Simon KA2，Jarowicz E3，Rotter K1，Szymanek-Pasternak A2，Zuwała-JagiełłoJ4。
作者信息

1
    波兰弗罗茨瓦夫地区特殊医院传染病科1。
2
    弗罗茨瓦夫医科大学传染病与肝病学系，波兰弗罗茨瓦夫。
3
    波兰弗罗茨瓦夫地区特殊医院传染病科2。
4
    弗罗茨瓦夫医科大学药物生物化学系，波兰弗罗茨瓦夫。

抽象

据估计，慢性乙型肝炎病毒（HBV）感染和HBV相关性肝病影响全世界约2.4亿人。现在已有疫苗可用，新的HBV感染病例数量急剧下降。然而，仍然存在HBV发病率非常高的地区。肝细胞癌（HCC）是男性中第四至六种最常见的恶性肿瘤，也是全球女性中第九位最常见的恶性肿瘤。所有HCC病例中有54％与HBV相关，使其成为全球癌症的最常见原因。乙型肝炎治疗可防止慢性肝炎进展为肝硬化和HCC发展，但即使HBV治疗效果最好，这些患者仍有患HCC的风险。在经动脉化疗栓塞（TACE），肝切除术（肝切除术）或肝移植术后的患者中，乙型肝炎病毒（HBV）的抑制也可提高患者的生存率。在本文中，我们介绍了目前HCC和HBV治疗的可能性，它们可以提高生存率和生活质量。
关键词：

HBV治疗; HCC; HCC治疗

结论：
    30324148
PMCID：
    PMC6185928
DOI：
    10.5114 / ceh.2018.78127